Malignant triton tumor (MTT) is a variant of the peripheral nerve sheath tumor. It is very uncommon but shows an aggressive course and limited survival. Half of the cases present symptoms related to neurofibromatosis type 1 disease. There is no standardized treatment, but multimodal approach is the best option. We present the case of a primary MTT located in the kidney, in a 43-year-old woman who received neoadjuvant chemotherapy as first-line treatment followed by surgical resection and adjuvant chemotherapy.

Keywords:
Malignant triton tumor, Peripheral nerve sheath tumor, Kidney tumor, Rhabdomyoblastic differentiation
1.
Woodruff JM, Chernik NL, Smith MC, Millett WB, Foote FW Jr: Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant ‘triton' tumors). Cancer 1973;32:426-439.
2.
Stasik CJ, Tawfik O: Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med 2006;130:1878-1881.
3.
Yakulis R, Manack L, Murphy AI Jr: Postradiation malignant triton tumor. A case report and review of the literature. Arch Pathol Lab Med 1996;120:541-548.
4.
Smith RE, Kebriaei MA, Gard AP, Mccomb RD, Bridge JA, Lennarson PJ: Intracranial malignant triton tumor in a patient with neurofibromatosis type 1: case report and review of the literature. Brain Tumor Pathol 2014;31:149-154.
5.
Thoennissen NH, Schliemann C, Brunnberg U, et al: Chemotherapy in metastatic malignant triton tumor: report on two cases. Oncol Rep 2007;18:763-767.
6.
Haddadin MH, Hawkins AL, Long P, et al: Cytogenetic study of malignant triton tumor: a case report. Cancer Genet Cytogenet 2003;144:100-105.
7.
McConnell YJ, Giacomantonio CA: Malignant triton tumors - complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012;106:51-56.
8.
Kamran SC, Howard SA, Shinagare AB, et al: Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. Eur J Surg Oncol 2013;39:46-52.
9.
Brotelle T, Bay JO: [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas]. Bull Cancer 2014;101:641-646.
10.
Siurala M, Bramante S, Vassilev L, et al: Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int J Cancer 2015;136:945-954.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.